Evidence map›Paper›PMID 24732780›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014

Isolated clonal cytogenetic abnormalities after high-dose therapy.

Margaret M Showel, Robert A Brodsky, Hua-Ling Tsai, Katlyn M Briel, Jeanne Kowalski, Constance A Griffin, Richard J Jones

Abstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  3. [Progress in pre-myelodysplastic syndrome conditions].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
    Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Margaret M ShowelSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Electronic address: mshowel1@jhmi.edu.
Robert A BrodskyDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Hua-Ling TsaiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Katlyn M BrielSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Jeanne KowalskiDepartment of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Constance A GriffinSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Richard J JonesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Funding

TUMOR VACCINESP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI HESS, ALLAN D · 1985 to 2016
$38.1M
NCI NIH HHS P01 306 CA15396NCI NIH HHS P01 CA015396
6 · The paper itself

Abstract

Therapy-related myeloid neoplasms (t-MN) are well-recognized complications of high-dose cytotoxic therapy (HDT), such as autologous stem cell transplantation (ASCT). Clonal marrow cytogenetic abnormalities (CMCA) in the setting of normal bone marrow pathology have also been reported after HDT, but their significance remains unclear. We retrospectively evaluated occurrences of CMCA and t-MN in 785 patients treated with HDT at Johns Hopkins University between 1997 and 2007. Most patients received ASCT, but 106 patients who received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institutional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. Twenty-two patients developed t-MN, with an estimated cumulative incidence of 3.5% at 4 years. Eleven patients developed isolated CMCA, either transient or persistent without pathologic evidence of t-MN. Altogether, only 20 of the patients with reported CMCA subsequently developed t-MN during the follow-up period. Therefore, in the absence of pathologic evidence of t-MN, CMCA should not be considered diagnostic of t-MN.

Indexed as

Chromosome AberrationsCombined Modality TherapyDisease-Free SurvivalFemaleHumansMaleMiddle AgedRetrospective StudiesChromosomal alterations in myeloid neoplasmsClonal cytogenetic abnormalitiesTreatment-related myeloid neoplasms

Identifiers

PMID24732780
PMCPMC4149219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.